Literature DB >> 18489610

Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.

Tomohide Abe1, Takayuki Seo, Takateru Ishitsu, Takehiro Nakagawa, Masaharu Hori, Kazuko Nakagawa.   

Abstract

AIMS: To establish whether the SCN1A IVS5-91 G > A polymorphism of the SCN1A gene, which encodes the neuronal sodium channel alpha subunit, affects responsiveness to the antiepileptic drugs (AEDS) carbamazepine and/or phenytoin.
METHODS: SCN1A IVS5-91 G > A polymorphism was genotyped in 228 Japanese epileptic patients treated with AEDs. The association between AED responsiveness and the polymorphism was estimated by logistic regression analysis, adjusting for clinical factors affecting the outcome of AED therapy.
RESULTS: The frequency of the AA genotype was significantly higher in carbamazepine-resistant patients (odds ratio, 2.7; 95% confidence interval (CI), 1.1, 7.1) and was insignificantly higher in AED-resistant patients.
CONCLUSIONS: This is the first report demonstrating an association between the SCN1A polymorphism and carbamazepine-resistant epilepsy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489610      PMCID: PMC2492927          DOI: 10.1111/j.1365-2125.2008.03203.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.

Authors:  Takayuki Seo; Takateru Ishitsu; Nao Ueda; Naoyuki Nakada; Keigo Yurube; Kentaro Ueda; Kazuko Nakagawa
Journal:  Pharmacogenomics       Date:  2006-06       Impact factor: 2.533

2.  A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose.

Authors:  Sarah K Tate; Rinki Singh; Chin-Chuan Hung; John Jen Tai; Chantal Depondt; Gianpiero L Cavalleri; Sanjay M Sisodiya; David B Goldstein; Horng-Huei Liou
Journal:  Pharmacogenet Genomics       Date:  2006-10       Impact factor: 2.089

Review 3.  Sodium channels as molecular targets for antiepileptic drugs.

Authors:  D S Ragsdale; M Avoli
Journal:  Brain Res Brain Res Rev       Date:  1998-03

Review 4.  SCN1A mutations and epilepsy.

Authors:  John C Mulley; Ingrid E Scheffer; Steven Petrou; Leanne M Dibbens; Samuel F Berkovic; Louise A Harkin
Journal:  Hum Mutat       Date:  2005-06       Impact factor: 4.878

5.  Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

Authors:  Sarah K Tate; Chantal Depondt; Sanjay M Sisodiya; Gianpiero L Cavalleri; Stephanie Schorge; Nicole Soranzo; Maria Thom; Arjune Sen; Simon D Shorvon; Josemir W Sander; Nicholas W Wood; David B Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

6.  A novel mechanism underlying drug resistance in chronic epilepsy.

Authors:  Stefan Remy; Siegrun Gabriel; Bernd W Urban; Dirk Dietrich; Thomas N Lehmann; Christian E Elger; Uwe Heinemann; Heinz Beck
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

Review 7.  Molecular and cellular mechanisms of pharmacoresistance in epilepsy.

Authors:  Stefan Remy; Heinz Beck
Journal:  Brain       Date:  2005-11-29       Impact factor: 13.501

8.  Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A.

Authors:  Erin L Heinzen; Woohyun Yoon; Sarah K Tate; Arjune Sen; Nicholas W Wood; Sanjay M Sisodiya; David B Goldstein
Journal:  Am J Hum Genet       Date:  2007-04-03       Impact factor: 11.025

  8 in total
  18 in total

1.  Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up.

Authors:  Bo-Ting Zhou; Qiu-Hong Zhou; Ji-Ye Yin; Guo-Liang Li; Jian Qu; Xiao-Jing Xu; Ding Liu; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  CNS Neurosci Ther       Date:  2012-05-17       Impact factor: 5.243

2.  Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population.

Authors:  Ram Lakhan; Ritu Kumari; Usha K Misra; Jayanti Kalita; Sunil Pradhan; Balraj Mittal
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

3.  Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels.

Authors:  Ruchi Baghel; Sandeep Grover; Harpreet Kaur; Ajay Jajodia; Chitra Rawat; Ankit Srivastava; Suman Kushwaha; Rachna Agarwal; Sangeeta Sharma; Ritushree Kukreti
Journal:  CNS Neurosci Ther       Date:  2016-06-01       Impact factor: 5.243

4.  Association between two SCN1A polymorphisms and resistance to sodium channel blocking AEDs: a meta-analysis.

Authors:  Yi Bao; Xinzhu Liu; Zheng Xiao
Journal:  Neurol Sci       Date:  2018-03-26       Impact factor: 3.307

5.  SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs.

Authors:  Christopher H Thompson; Kristopher M Kahlig; Alfred L George
Journal:  Epilepsia       Date:  2011-03-31       Impact factor: 5.864

6.  Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population.

Authors:  Ritu Kumari; Ram Lakhan; R K Garg; J Kalita; U K Misra; Balraj Mittal
Journal:  Indian J Hum Genet       Date:  2011-05

7.  Alternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3-S4 linker.

Authors:  Emily V Fletcher; Dimitri M Kullmann; Stephanie Schorge
Journal:  J Biol Chem       Date:  2011-09-02       Impact factor: 5.157

8.  Influence of the SCN1A IVS5N + 5 G>A Polymorphism on Therapy with Carbamazepine for Epilepsy.

Authors:  Z Sterjev; G Kiteva; E Cvetkovska; I Petrov; I Kuzmanovski; Tj Ribarska; Ka Nestorovska; N Matevska; S Trajkovik-Jolevska; Aj Dimovski; Lj Suturkova
Journal:  Balkan J Med Genet       Date:  2012-06       Impact factor: 0.519

9.  Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.

Authors:  Hiroo Nakashima; Kentaro Oniki; Miki Nishimura; Naoki Ogusu; Masatsugu Shimomasuda; Tatsumasa Ono; Kazuki Matsuda; Norio Yasui-Furukori; Kazuko Nakagawa; Takateru Ishitsu; Junji Saruwatari
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

10.  Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients.

Authors:  Armond Daci; Giangiacomo Beretta; Driton Vllasaliu; Aida Shala; Valbona Govori; Giuseppe Danilo Norata; Shaip Krasniqi
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.